When was Frontera Therapeutics founded?

Frontera Therapeutics was founded in 2019 and raised its 1st funding round 3 years after it was founded.

Where is Frontera Therapeutics located?

Frontera Therapeutics is headquartered in Suzhou, China.

Who is the current CEO of Frontera Therapeutics?

Yong Dai of Frontera Therapeutics.

How many employees does Frontera Therapeutics have?

As of Jul 01, 2024, the latest employee count at Frontera Therapeutics is 51 - 200.

Is Frontera Therapeutics a funded company?

Frontera Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jun 24, 2022.

When was the latest funding round of Frontera Therapeutics?

Frontera Therapeutics' latest funding was a $***** Series B round on Jun 24, 2022, with participation from 5 investors.

Where does Frontera Therapeutics rank among its competitors?

Frontera Therapeutics ranks 226th amongst 2888 active competitors, of which 982 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Frontera Therapeutics?

Frontera Therapeutics' top competitors include Jazz Pharmaceuticals, BridgeBio and Alnylam. Among them, BridgeBio secured the most recent funding round in April, 2024.

Frontera Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of AAV-based gene therapies for the treatment of rare and chronic diseases. The company focuses on developing recombinant AVV products for the treatment of genetic disorders including those of ophthalmology, liver, metabolic, and neuromuscular diseases.

Website: fronteratherapeutics.com
Email ID: *****@fronteratherapeutics.com
Phone Number: +86 **********

Key Metrics

Founded Year

2019

Location

Suzhou, China

Stage

Series B

Total Funding

$195M in 1 round

Latest Funding Round

Series B, Jun 24, 2022, $*****

Investors

Sequoia Capital China & 5 more

Ranked

226^th among 2888 active competitors

Employee Count

51 - 200 as on Jul 01, 2024

Similar Companies

BridgeBio & 605 more

View Frontera Therapeutics' full profile

Frontera Therapeutics has raised a total funding of $195M over 1 round. Its latest funding round was a Series B round on Jun 24, 2022 for $*****. 5 investors participated in its latest round. Frontera Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Frontera Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 24, 2022	6265905	Series B	7409398	7827023	7479276	8453488

Access funding benchmarks and valuations. Sign up today!

View details of Frontera Therapeutics's funding rounds and investors

The founders of Frontera Therapeutics is Yong Dai.

Here are the details of Frontera Therapeutics' key team members:

Yong Dai: CEO, Founder and Executive Board Director of Frontera Therapeutics.

View details of Frontera Therapeutics's Founder profiles and Board Members

Frontera Therapeutics' employee count trend

Frontera Therapeutics has 51 - 200 employees as of Jul 24. Here is Frontera Therapeutics's employee count trend over the years:

Employee count trend for Frontera Therapeutics

Uncover Frontera Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Frontera Therapeutics include Jazz Pharmaceuticals, BridgeBio and Alnylam. Here is the list of Top 10 competitors of Frontera Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
5th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
7th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
8th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
10th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
226th	Frontera Therapeutics 2019, Suzhou (China), Series B	Developer of AAV-based gene therapies for the treatment of rare and chronic diseases	$195M	Boyu Capital, Orbimed & 4 others	57/100